Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

TheSuper Aug. 3 at 4:01 PM

$SLS Reading through the deck again this morning. 2 things that stand out to me. Pages 5-8 were EXACTLY like I have been saying for 6 months. GPS is being positioned to the world (and BP) as a WT1 treatment. You have to start somewhere on studies, and AML just happened to be that. This will play into a valuation of GPS for BO and treatment until relapse, on top of that, makes this an unbelievable oppurtunity. 2ndly I really feel like there is a good chance that this Frontline study will act as a confirmatory study for AA for R/R.

2 · Reply

R_NW Aug. 3 at 3:30 PM

$SLS Here is the link to the presentation, for those who haven't reviewed it yet. https://ir.sellaslifesciences.com/events-and-presentations/default.aspx

0 · Reply

330South Aug. 3 at 2:48 PM

$SLS long article in WSJ this weekend discussing drug price negotiations and how certain class of drugs are excluded from Medicare negotiations. SLS drugs should not be impacted by Trump Administration price negotiations until one of the drugs is expanded to multiple indications because they are currently orphan disease drugs, targeted at diseases with fewer than 200,000 patients in USA. Even after expansion to multiple indications, the drugs are exempted from negotiation for 9 or 13 years depending on the drugs designation. Seems positive for SLS that the drug price reductions requested by Trump are not legally required and shouldn’t impact SLS drugs for a long time after approval.

1 · Reply

samsha1 Aug. 3 at 2:27 PM

$SLS keytruda- The first indication for which Keytruda (pembrolizumab) was approved by the FDA was for the treatment of patients with unresectable or metastatic melanoma, specifically after progression on prior treatment with ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. This approval was granted on September 4, 2014. It was also the first human PD-1 blocking antibody approved for use in the United States. Value then for TAM $<0.5 B and now approved over 40 indications with some adinfinitum dosages

1 · Reply

UnsungProdigy Aug. 3 at 2:09 PM

$SLS

0 · Reply

jzg88 Aug. 3 at 1:51 PM

$SLS I think we all might have under estimate the arbitration case against 3D Med. From our side, 3D is the bad boy who didn’t perform according to the contract. But from 3D’s side, it feels that it’s not their fault that they couldn’t perform the contract due to government lockdown laws during Covid. Both sides felt they had a reasonable case but not a clear cut case to win, and that’s why they agreed to an arbitration settlement. Otherwise SLS could simply sue 3D in a court (even in a court in China) if SLS felt it had a clear case to win. @Supporter67 Yes all three versions of the presentation have the same content about 3D on page 17.

3 · Reply

WW789 Aug. 3 at 1:25 PM

$SLS

0 · Reply

Notanymore Aug. 3 at 12:55 PM

$SLS … until disease relapse….

0 · Reply

takeshoot Aug. 3 at 11:52 AM

$SLS It looks like they have exercised an additional 5.2 million warrants since May.

5 · Reply

RealImbackbears Aug. 3 at 11:00 AM

$SLS where is the guy that works for anson that has a used furniture fetish where the CEO sat and CFO J.B also the gps guy that sat it's ass on SLS furniture and is the only retail shareholder that can attend private conferences with the CEO?

1 · Reply

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 2 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 2 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 2 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 2 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 2 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 3 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 3 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 4 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 4 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 4 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 5 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 6 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 6 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 7 months ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 8 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 8 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 8 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 9 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 9 months ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 9 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 10 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 10 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Jan 25, 2024, 8:45 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

Jan 9, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 4, 2024, 9:01 AM EST - 1 year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Jan 3, 2024, 8:05 PM EST - 1 year ago

SELLAS Life Sciences Announces Proposed Public Offering

Jan 3, 2024, 7:30 AM EST - 1 year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Dec 27, 2023, 8:55 AM EST - 1 year ago

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Dec 21, 2023, 8:15 AM EST - 1 year ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

TheSuper Aug. 3 at 4:01 PM

2 · Reply

R_NW Aug. 3 at 3:30 PM

$SLS Here is the link to the presentation, for those who haven't reviewed it yet. https://ir.sellaslifesciences.com/events-and-presentations/default.aspx

0 · Reply

330South Aug. 3 at 2:48 PM

1 · Reply

samsha1 Aug. 3 at 2:27 PM

1 · Reply

UnsungProdigy Aug. 3 at 2:09 PM

$SLS

0 · Reply

jzg88 Aug. 3 at 1:51 PM

3 · Reply

WW789 Aug. 3 at 1:25 PM

$SLS

0 · Reply

Notanymore Aug. 3 at 12:55 PM

$SLS … until disease relapse….

0 · Reply

takeshoot Aug. 3 at 11:52 AM

$SLS It looks like they have exercised an additional 5.2 million warrants since May.

5 · Reply

RealImbackbears Aug. 3 at 11:00 AM

1 · Reply

finarch Aug. 3 at 10:56 AM

$SLS ffs another classic

0 · Reply

Harvard_MBA Aug. 3 at 10:34 AM

$SLS If GPS is so great why did Merck, Bristol and 3D Meds take the f*ck off after their combo studies ended? I'll tell you why, they got up close to Sellas and said no thanks. In fact, 3D Meds just stiffed Sellas on their payment. In other words they cut their losses. I'm afraid your investment has been decimated. Today is Sunday and I'd be going to church and ask for your forgiveness for outright greed.

1 · Reply

JRUKUKUK Aug. 3 at 8:05 AM

$SLS not seen anyone do this yet, apologies if they have. Ran a check of the 3 new KOLs past and present work/associations for a common BP. We have a winner in Bristol Myers Squibb (BMS). I’m going to hypothesis’s that this company is our GPS purchaser, possibly SLS009 at the same time.

7 · Reply

Torben96 Aug. 3 at 7:43 AM

$SLS Everybody is talking about the calls. Isnt it possible that the warrant holders are selling those calls ? There are about 70 million warrants open and 25 million calls open, the warrant ho,der so far earned very much money with the calls. There are so many cheap warrant between 1,2 - 1,72 open, they can execute the warrants and deliver all calls without a big squeeze or gamma squeeze. Also the 25 million shorts could be delivered from the warrant holders. If somebody is selling naked calls it could be suicide. What everybody things ?

3 · Reply

Supporter67 Aug. 3 at 7:31 AM

$SLS Slide 17 / 3D Medicines The presentation has 34 slides. A lot of information. Why the info of slide 17 in case they will never pay ? In that case just leave it and just make 33 slides. Maybe because the chances are better now that 3D is still on board and going to pay the $13 million. Maybe no penalty but at least the $13 million. Maybe that‘s the deal ? Better $13 million than nothing !

1 · Reply

Supporter67 Aug. 3 at 7:13 AM

$SLS GPS statements. Not congruent : Slide 3 Final analysis expected in 2025 - 80 events. Slide 12 The next and final analysis will be conducted once 80 events (deaths) are reached. Slide 31 Next and final analysis: expected by year-end 2025 What now , 80 events or year-end 2025 ??

2 · Reply

Marcus737 Aug. 3 at 6:51 AM

$SLS Presentation: Potential GPS label expansion post cr1 and transplant. If FA data are good. That will give GPS 10000 patients.

0 · Reply

TheFrogPrince Aug. 3 at 3:53 AM

$SLS To add, AA starts the ‘market exclusivity period’ since it’s the FDA slapping its approval on the drug. For reference, imagine if Keytruda had a whole additional year left on their exclusivity period. That’s a lot of money to a buying organization, especially if these turn out like it looks like they will.

0 · Reply

vlucky16 Aug. 3 at 3:36 AM

$SLS Big Pharma could have bought SLS on the cheap at phase 2 maybe! But they chose to wait for more results or did other deals first. Now it's going to cost them late stage PH 3 GPS exceeding OS to maintenance status, early Phase 2 009 with possible AA. The only thing having people guessing is the Manipulated Market Cap. If we impose SEC tariffs on entities from other countries trading in our free market maybe that would stop some of the manipulation?

0 · Reply

Gps_100X_ROI_Potential Aug. 3 at 3:28 AM

$SLS as an FYI - SLS can Submit a BLA to the FDA for SLS009 ANY TIME THEY WANT TO - if they believe the Data is Strong Enough. - And it IS.

0 · Reply

samsha1 Aug. 3 at 3:14 AM

$SLS SLS 009 and especially GPS should have a ready to launch roll out. BO soon. The $20 B valuation is a reality.

3 · Reply

cea Aug. 3 at 2:43 AM

$SLS Reposting this…similar thinking to my prior stated musing from earlier today. Thank you @Lovdoc31.

1 · Reply

Market Cap	165.63M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,848,700
Avg Vol	3,081,200
Day's Range	N/A - N/A
Shares Out	99.78M
Stochastic %K	25%
Beta	2.26
Analysts	Strong Sell
Price Target	$6.83